4-乙基-2H-二氮杂萘-1-酮 | 54145-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-乙基-2H-二氮杂萘-1-酮
• 英文名称: 4-ethyl-1(2H)-phthalazinone
• 英文别名: 4-ethyl-2H-phthalazin-1-one；4-ethylphthalazine-1(2H)-one；1-Ethyl-phthalaz-4-on；4-Ethyl-phthalazin-2H-1-on；4-Aethyl-2H-phthalazin-1-on
• CAS: 54145-30-1
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD00458080
• 分子量: 174.202
• InChiKey: UIRVNHJZFRDWBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  存储条件：2-8°C，干燥且密封。

反应信息

• 作为反应物：
  描述：

  4-乙基-2H-二氮杂萘-1-酮 在 palladium on activated charcoal 哌啶 、 氢气 、 potassium carbonate 、 苯甲酸 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 20.0~70.0 ℃ 、413.68 kPa 条件下， 反应 25.5h， 生成 5-[4-[2-[4-Ethyl-1-oxo-1,2-dihydro-phthalazin-2-yl]ethoxy]phenyl methyl]thiazolidin-2,4-dione
  参考文献：
  名称：

  Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents

  摘要：

  We report here the synthesis of a series of 5-[4-[2-[substituted phthalazinones-2(or 4)yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and 5-[4-[2-[2,3-benzoxazine-4-one-2-yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and their plasma glucose and plasma triglyceride lowering activity in db/db mice. In vitro PPAR gamma transactivation assay was performed in HEK 293T cells. In vitro and in vivo pharmacological studies showed that the phthalazinone analogue has better activity. PHT46 (compound 5a), the best compound in this series, showed better in vitro PPAR gamma transactivation potential than troglitazone and pioglitazone. In insulin resistant db/db mice, PHT46 showed better plasma glucose and triglyceride lowering activity than the standard drugs. Pharmacokinetic study in Wistar rats showed good systemic exposure of PHT46. Subchronic toxicity study in Wistar rats did not show any treatment-related adverse effect. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01257-0
• 作为产物：
  描述：

  氨基邻苯二甲胺 在 ammonium chloride 作用下， 以 乙醇 为溶剂， 反应 13.0h， 生成 4-乙基-2H-二氮杂萘-1-酮
  参考文献：
  名称：

  Kandile, Nadia Gharib, Acta Chimica Hungarica, 1989, vol. 126, # 4, p. 533 - 538

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021239885A1

  公开（公告）日：2021-12-02

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  本发明涉及用于抑制NLRP3炎症体产生的新化合物，其中所述化合物由公式（I）定义，其中整数R1、R2和R3在描述中定义，且所述化合物可用作药物，例如用于治疗与NLRP3炎症体活性相关的一种疾病或失调。
• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• 一种4-取代酞嗪酮衍生物的制备方法及应用
  申请人：安徽工业大学

  公开号：CN113549015B

  公开（公告）日：2023-07-14

  本发明公开了一种4‑取代酞嗪酮衍生物的制备方法及应用，属于有机合成领域。所述方法为：(1)将N1，N2‑二甲氧基‑N1，N2‑二甲基邻苯二甲酰胺类物质与含格式试剂在有机溶剂中混合反应一段时间；(2)再将步骤(1)得到的产物与水合肼混合，并在醇类溶剂中加热后得到4‑取代酞嗪酮衍生物。本发明的第一步反应不需要零度以下的低温，对反应当量比和滴加顺序没有严格要求，没有过度反应的中间产物生成，中间产物易提纯，且反应对底物的适用范围广，使得本发明的工艺更容易实现工业化生产，得到的产物在制备抗组胺药物、抗癌药物、合成金属有机化合物的配体以及合成聚芳醚的单体上有广泛的应用。
• Heterocyclic compounds having antidiabetic hypolipidemic
  申请人：Dr. Reddy's Research Foundation

  公开号：US06011036A1

  公开（公告）日：2000-01-04

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their analogues, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione compounds of the general formula (I), and their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、它们的类似物、它们的衍生物、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮化合物及其类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的制剂。##STR1##
• PHTHALAZINONE DERIVATIVES
  申请人：Javaid Muhammad Hashim

  公开号：US20090163477A1

  公开（公告）日：2009-06-25

  A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NR X or CR X R Y ; if X═NR X then n is 1 or 2 and if X═CR X R Y then n is 1; R X is selected from the group consisting of H, optionally substituted C 1-20 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R Y is selected from H, hydroxy, amino; or R X and R Y may together form a spiro-C 3-7 cycloalkyl or heterocyclyl group; R C1 and R C2 are independently selected from the group consisting of hydrogen and C 1-4 alkyl, or when X is CR X R Y , R C1 , R C1 , R C2 , R X and R Y , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R 1 is selected from H and halo; and Het is selected from: where Y 1 is selected from CH and N, Y 2 is selected from CH and N, Y 3 is selected from CH, CF and N, where only one or two of Y 1 , Y 2 and Y 3 can be N; and where Q is O or S.

  公式（I）的化合物：用于治疗由于PARP抑制而改善的癌症或其他疾病，其中：A和B共同表示一个可选取的，融合芳香环；X可以是NRX或CRXRY；如果X═NRX，则n为1或2，如果X═CRXRY，则n为1；RX从H，可选取的取代C1-20烷基，C5-20芳基，C3-20杂环基，酰胺，硫酰胺，酯，酰基和磺酰基组中选择；RY从H，羟基，氨基中选择；或者RX和RY可以共同形成一个螺旋C3-7环烷基或杂环基；RC1和RC2从氢和C1-4烷基中独立选择，或者当X为CRXRY时，RC1，RC1，RC2，RX和RY可以与它们附着的碳原子共同形成一个可选取的融合芳香环；R1从H和卤素中选择；Het从以下中选择：其中Y1从CH和N中选择，Y2从CH和N中选择，Y3从CH，CF和N中选择，其中只有一个或两个Y1，Y2和Y3可以是N；并且Q为O或S。